Acquiring Company
Novartis
Acquired Company
Tourmaline Bio
Switzerland
New YorkBiotechnologyHealth CarepharmaceuticalsBiotechnologyHealth CareTherapeuticsDescription
Novartis AG has entered into a merger agreement to acquire Tourmaline Bio, Inc. for $48.00 per share in cash, valuing the total equity at approximately $1.4 billion. The transaction is expected to complete in the fourth quarter of 2025, pending customary closing conditions. Tourmaline Bio will continue to operate independently until the merger is finalized.
Quick answer
Novartis is acquiring Tourmaline Bio for $1.4 billion, announced September 9, 2025. Novartis is based in Switzerland.
- How much did Novartis pay for Tourmaline Bio?
- The reported deal value is $1.4 billion.
- What does Novartis do?
- Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel.
- Where are Novartis and Tourmaline Bio based?
- Novartis is based in Switzerland. Tourmaline Bio is based in New York, United States.
- Who are the decision-makers at Novartis?
- Fundz holds 1 contact at Novartis. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in pharmaceuticals and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Novartis to acquire Tourmaline Bio in tender offer (October 22, 2025)
- Pfizer acquires Metsera for $7.3 billion, $7.3B (October 13, 2025)
- Novartis to acquire Tourmaline Bio for $48 per share (September 29, 2025)
- Pfizer to acquire Metsera for $7.3 billion, $7.3B (September 22, 2025)
- AbbVie completes acquisition of Capstan Therapeutics (August 19, 2025)
- Supernus acquires SAGE Therapeutics for USD 8.50/share (July 31, 2025)
Who to call at Novartis, and when
When Novartis changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Novartis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Novartis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Novartis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Novartis makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Tourmaline Bio?
Tourmaline Bio was acquired by Novartis, based in Switzerland. The deal was reported on September 9, 2025. Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel. Novartis is publicly traded (NVS) and operates in Biotechnology.
When did Novartis acquire Tourmaline Bio?
Novartis's acquisition of Tourmaline Bio was reported on September 9, 2025. Novartis AG has entered into a merger agreement to acquire Tourmaline Bio, Inc. for $48.00 per share in cash, valuing the total equity at approximately $1.4 billion. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Tourmaline Bio do?
Tourmaline Bio is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients. It is privately held, operating in Biotechnology, and is based in New York.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.